275 related articles for article (PubMed ID: 15126436)
1. Long-term efficacy of BCG vaccine in American Indians and Alaska Natives: A 60-year follow-up study.
Aronson NE; Santosham M; Comstock GW; Howard RS; Moulton LH; Rhoades ER; Harrison LH
JAMA; 2004 May; 291(17):2086-91. PubMed ID: 15126436
[TBL] [Abstract][Full Text] [Related]
2. Association of BCG Vaccination in Childhood With Subsequent Cancer Diagnoses: A 60-Year Follow-up of a Clinical Trial.
Usher NT; Chang S; Howard RS; Martinez A; Harrison LH; Santosham M; Aronson NE
JAMA Netw Open; 2019 Sep; 2(9):e1912014. PubMed ID: 31553471
[TBL] [Abstract][Full Text] [Related]
3. BCG vaccination among Canadian Indians and Inuit: the epidemiological bases for policy decision.
Young TK
Can J Public Health; 1985; 76(2):124-9. PubMed ID: 4005772
[TBL] [Abstract][Full Text] [Related]
4. Systematic review and meta-analysis of the current evidence on the duration of protection by bacillus Calmette-Guérin vaccination against tuberculosis.
Abubakar I; Pimpin L; Ariti C; Beynon R; Mangtani P; Sterne JA; Fine PE; Smith PG; Lipman M; Elliman D; Watson JM; Drumright LN; Whiting PF; Vynnycky E; Rodrigues LC
Health Technol Assess; 2013 Sep; 17(37):1-372, v-vi. PubMed ID: 24021245
[TBL] [Abstract][Full Text] [Related]
5. The efficacy of bacillus Calmette-Guérin vaccination of newborns and infants in the prevention of tuberculosis: meta-analyses of the published literature.
Colditz GA; Berkey CS; Mosteller F; Brewer TF; Wilson ME; Burdick E; Fineberg HV
Pediatrics; 1995 Jul; 96(1 Pt 1):29-35. PubMed ID: 7596718
[TBL] [Abstract][Full Text] [Related]
6. The Long-term Effect of Bacille Calmette-Guérin Vaccination on Tuberculin Skin Testing: A 55-Year Follow-Up Study.
Mancuso JD; Mody RM; Olsen CH; Harrison LH; Santosham M; Aronson NE
Chest; 2017 Aug; 152(2):282-294. PubMed ID: 28087302
[TBL] [Abstract][Full Text] [Related]
7. Prevention of M. tuberculosis Infection with H4:IC31 Vaccine or BCG Revaccination.
Nemes E; Geldenhuys H; Rozot V; Rutkowski KT; Ratangee F; Bilek N; Mabwe S; Makhethe L; Erasmus M; Toefy A; Mulenga H; Hanekom WA; Self SG; Bekker LG; Ryall R; Gurunathan S; DiazGranados CA; Andersen P; Kromann I; Evans T; Ellis RD; Landry B; Hokey DA; Hopkins R; Ginsberg AM; Scriba TJ; Hatherill M;
N Engl J Med; 2018 Jul; 379(2):138-149. PubMed ID: 29996082
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of BCG vaccination of the newborn: evaluation by a follow-up study of contacts in Bangui.
Lanckriet C; Lévy-Bruhl D; Bingono E; Siopathis RM; Guérin N
Int J Epidemiol; 1995 Oct; 24(5):1042-9. PubMed ID: 8557438
[TBL] [Abstract][Full Text] [Related]
9. Using BCG vaccine to enhance non-specific protection of health care workers during the COVID-19 pandemic: A structured summary of a study protocol for a randomised controlled trial in Denmark.
Madsen AMR; Schaltz-Buchholzer F; Benfield T; Bjerregaard-Andersen M; Dalgaard LS; Dam C; Ditlev SB; Faizi G; Johansen IS; Kofoed PE; Kristensen GS; Loekkegaard ECL; Mogensen CB; Mohamed L; Ostenfeld A; Oedegaard ES; Soerensen MK; Wejse C; Jensen AKG; Nielsen S; Krause TG; Netea MG; Aaby P; Benn CS
Trials; 2020 Sep; 21(1):799. PubMed ID: 32943115
[TBL] [Abstract][Full Text] [Related]
10. A case-control study to evaluate the effectiveness of mass neonatal BCG vaccination among Canadian Indians.
Young TK; Hershfield ES
Am J Public Health; 1986 Jul; 76(7):783-6. PubMed ID: 3717464
[TBL] [Abstract][Full Text] [Related]
11. Revisiting the Chingleput BCG vaccination trial for the impact of BCG revaccination on the incidence of tuberculosis disease.
Velayutham B; Thiruvengadam K; Kumaran PP; Watson B; Rajendran K; Padmapriyadarsini C
Indian J Med Res; 2023; 157(2&3):152-159. PubMed ID: 36124494
[TBL] [Abstract][Full Text] [Related]
12. Observational study to estimate the changes in the effectiveness of bacillus Calmette-Guérin (BCG) vaccination with time since vaccination for preventing tuberculosis in the UK.
Mangtani P; Nguipdop-Djomo P; Keogh RH; Trinder L; Smith PG; Fine PE; Sterne J; Abubakar I; Vynnycky E; Watson J; Elliman D; Lipman M; Rodrigues LC
Health Technol Assess; 2017 Jul; 21(39):1-54. PubMed ID: 28738015
[TBL] [Abstract][Full Text] [Related]
13. A systematic review of BCG vaccination policies among high-risk groups in low TB-burden countries: implications for vaccination strategy in Canadian indigenous communities.
Faust L; Schreiber Y; Bocking N
BMC Public Health; 2019 Nov; 19(1):1504. PubMed ID: 31711446
[TBL] [Abstract][Full Text] [Related]
14. The effectiveness of bacillus Calmette-Guérin (BCG) vaccination against tuberculosis. A case-control study in Treaty Indians, Alberta, Canada.
Houston S; Fanning A; Soskolne CL; Fraser N
Am J Epidemiol; 1990 Feb; 131(2):340-8. PubMed ID: 2296986
[TBL] [Abstract][Full Text] [Related]
15. The lack of association between bacille Calmette-Guerin vaccination and clustering of Aboriginals with tuberculosis in western Canada.
Cook VJ; Hernández-Garduño E; Kunimoto D; Hershfield ES; Fanning EA; Hoeppner VH; Elwood RK; FitzGerald JM;
Can Respir J; 2005 Apr; 12(3):134-8. PubMed ID: 15875064
[TBL] [Abstract][Full Text] [Related]
16. Duration of BCG protection against tuberculosis and change in effectiveness with time since vaccination in Norway: a retrospective population-based cohort study.
Nguipdop-Djomo P; Heldal E; Rodrigues LC; Abubakar I; Mangtani P
Lancet Infect Dis; 2016 Feb; 16(2):219-26. PubMed ID: 26603173
[TBL] [Abstract][Full Text] [Related]
17. Determinants of tuberculosis trends in six Indigenous populations of the USA, Canada, and Greenland from 1960 to 2014: a population-based study.
Dehghani K; Lan Z; Li P; Michelsen SW; Waites S; Benedetti A; Lejeune P; Torrie J; Robinson E; Vejvoda B; Mullah M; Redwood D; Cooper M; Fanning A; Yacoub W; Alvarez GG; Søborg B; Long R; Menzies D
Lancet Public Health; 2018 Mar; 3(3):e133-e142. PubMed ID: 29426597
[TBL] [Abstract][Full Text] [Related]
18. Serious adverse events associated with bacille Calmette-Guérin vaccine in Canada.
Deeks SL; Clark M; Scheifele DW; Law BJ; Dawar M; Ahmadipour N; Walop W; Ellis CE; King A
Pediatr Infect Dis J; 2005 Jun; 24(6):538-41. PubMed ID: 15933565
[TBL] [Abstract][Full Text] [Related]
19. The benefits and risks of bacille Calmette-Guérin vaccination among infants at high risk for both tuberculosis and severe combined immunodeficiency: assessment by Markov model.
Clark M; Cameron DW
BMC Pediatr; 2006 Mar; 6():5. PubMed ID: 16515694
[TBL] [Abstract][Full Text] [Related]
20. Adverse reactions to the Bacillus Calmette-Guérin (BCG) vaccine in new-born infants-an evaluation of the Danish strain 1331 SSI in a randomized clinical trial.
Nissen TN; Birk NM; Kjærgaard J; Thøstesen LM; Pihl GT; Hoffmann T; Jeppesen DL; Kofoed PE; Greisen G; Benn CS; Aaby P; Pryds O; Stensballe LG
Vaccine; 2016 May; 34(22):2477-82. PubMed ID: 27060379
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
